UK biotech NeRRe Therapeutics has determined to streamline its R&D portfolio by establishing a brand-new company specializing in women’s health.
The new company, referred to as KaNDy Therapeutics, makes its official debut at this time and can deal with the event of NT-814, considered one of two part 2 candidates developed at NeRRe. It is billed as a first-in-class neurokinin-1,three receptor antagonist with potential to deal with postmenopausal vasomotor signs (PMVMS) resembling scorching flashes and sleep disturbances.
That leaves NeRRe—which itself spun out of GlaxoSmithKline (GSK) in 2012 after the large pharma company determined to withdraw from neuroscience R&D—focusing its actions on its NK-1 antagonist program for neuronal hypersensitivity headed by orvepitant.
The new company’s managing director Mary Kerr (pictured), who moved to NeRRe from GSK, explains the rationale for the choice to bisect the enterprise. “It was clear during the Series B raise that very few investors had an interest to invest in both sides of the NeRRe portfolio,” she tells FierceBiotech.
“In fact, one year ago it was difficult to find anyone interested in women’s health at all, but that has changed in recent months,” she provides, pointing to current developments corresponding to Astellas’ acquisition of PMVMMS drug developer Ogeda, and IPOs for endometriosis drug developer Myovant and Obseva, a reproductive health specialist.
The two corporations have the identical shareholder base for now, however there’s now flexibility for this to diversify and prolong if mandatory, and separating out NT-814 will present “differential investment, including access to capital and IPO markets.”
NT-814 has the potential to turn into an essential new therapeutic in women’s health as neurokinin antagonism represents one of many few novel targets in the sector for greater than 20 years, and will turn out to be a once-daily, non-hormonal remedy for post-menopausal signs.
The drug is heading for a part 2b trial that may check its means to scale back the frequency and severity of scorching flashes at 4 and 12 weeks, with outcomes anticipated inside the subsequent 12 to 18 months. In that timeframe KaNDy may begin preliminary research in potential follow-up indications, which might embrace endometriosis and polycystic ovary syndrome (PCOS).
“For many women, menopausal symptoms such as hot flashes are debilitating and long-lasting, and can have a major impact on quality of life,” commented Professor Richard Anderson, a women’s health specialist on the University of Edinburgh and medical advisor to KaNDy.
“As a potential once daily alternative to HRT without the issues surrounding hormone replacement, NT-814 could bring them considerable relief.”
KaNDY is chaired by Iain Dukes, enterprise companion at OrbiMed, and is predicated on the Stevenage Bioscience Catalyst in the UK.